Frontotemporal Dementia (FTD) News and Research

RSS

Alector announces initiation of Phase 1 trial of AL001 for treating frontotemporal dementia

Alector, a privately held biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration, today announced the initiation of its Phase 1 trial called INFRONT, which is evaluating AL001, the company's product candidate for the treatment of a genetically-defined sub-population of patients with frontotemporal dementia.

19 Sep 2018

Study provides new clues to connection between aging and neurodegeneration

For decades researchers have worked to shed light on the causes of neurodegenerative disorders, a group of devastating conditions, including Alzheimer's and Parkinson's, that involve the progressive loss of neurons and nervous system function. In recent years, numerous factors, from genetic mutations to viral infections, have been found to contribute to the development of these diseases.

23 Aug 2018

Study reveals surprising insights into RNA-binding proteins

A host of special molecules called nuclear RNA-binding proteins (RBPs), when misplaced outside the nucleus, form the harmful clumps seen in several brain disorders, including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).

20 Apr 2018

NIH-funded researchers use CRISPR to rapidly find new genetic suspects behind ALS, FTD

NIH-funded researchers at Stanford University used the gene editing tool CRISPR-Cas9 to rapidly identify genes in the human genome that might modify the severity of amyotrophic lateral sclerosis and frontotemporal dementia caused by mutations in a gene called C9orf72.

13 Mar 2018

Study reveals key function of ALS-linked protein

The protein FUS, whose mutation or disruption causes many cases of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), works as a central component of one of the most important regulatory systems in cells, according to a new study in Molecular Cell from scientists at Johns Hopkins Bloomberg School of Public Health.

8 Mar 2018

Researchers develop drug that supports cellular traffic jam theory in ALS/FTD

Neurodegeneration in ALS/FTD may be caused by TDP-43 aggregation in the cytoplasm, causing cellular traffic jams. The trial drug can sequester TDP-43.

9 Jan 2018

Scientists develop novel mouse model to capture pathology of sporadic ALS and FTD

Neurodegenerative diseases are incurable and debilitating conditions that result in progressive degeneration and death of nerve cells, which leads to problems with movement or mental functioning. Examples include Alzheimer's, Parkinson's, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

13 Nov 2017

Researchers propose LSD1 protein as central player in Alzheimer's and FTD

Removal of a regulatory gene called LSD1 in adult mice induces changes in gene activity that that look unexpectedly like Alzheimer's disease, scientists have discovered.

9 Oct 2017

Scientists identify basic biological mechanism that kills neurons in ALS

A team led by scientists at St. Jude Children's Research Hospital and Mayo Clinic has identified a basic biological mechanism that kills neurons in amyotrophic lateral sclerosis (ALS) and in a related genetic disorder, frontotemporal dementia (FTD), found in some ALS patients.

16 Aug 2017

Emory scientists use new tools to detect granulins for the first time inside cells

Emory University School of Medicine researchers have developed tools that enable them to detect small proteins called granulins for the first time inside cells.

14 Aug 2017

TSRI scientist and partners receive $7.2 million grant to create new RNA-based treatments for ALS

Professor Matthew Disney of the Department of Chemistry on the Florida campus of The Scripps Research Institute, together with scientists from Mayo Clinic's Florida campus and Johns Hopkins School of Medicine, has been awarded $7.2 million from the National Institute of Neurological Disorders and Stroke of The National Institutes of Health to create new RNA-based treatments for the most common form of amyotrophic lateral sclerosis (ALS), as well as a type of frontotemporal dementia (FTD).

15 Jun 2017

Study shows how RNA splicing errors may trigger development of ALS, FTD

The most frequent genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD)- rare and related neurological disorders marked by progressive deterioration of motor or cognitive abilities- may be due to errors in RNA splicing, an intermediary step for translating genetic instructions into functional proteins.

14 Jun 2017

Study underlines significance of microglia for homeostasis in the brain

The role of microglial cells in neurodegenerative disease is not fully understood. But new results from researchers in Munich and Basel suggest that stimulation of this arm of the immune system might well delay the onset of such disorders.

2 Jun 2017

Gladstone scientists discover common mechanism that links neurodegeneration in young and old

Scientists at the Gladstone Institutes and the University of California, San Francisco (UCSF), identified a common mechanism in two forms of neurodegeneration that affect young adults or the elderly.

12 Apr 2017

Children of parents affected with C9orf72 mutations more likely to have FTD and ALS at younger age

The most common genetic cause of the brain diseases frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) is a mutation in the C9orf72 gene.

14 Feb 2017

Researchers discover how toxic proteins linked to neurological diseases impair membrane-less organelles

Researchers at St. Jude Children's Research Hospital have discovered the way toxic proteins linked to the most common forms of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) incapacitate membrane-less organelles inside cells.

21 Oct 2016

Research findings may have implications for ALS and other neurological disorders

Amyotrophic lateral sclerosis (ALS, or Lou Gehrig's disease) is a progressive disorder that devastates motor nerve cells. People diagnosed with ALS slowly lose the ability to control muscle movement, and are ultimately unable to speak, eat, move, or breathe.

4 Aug 2016

Scientists uncover novel sites of expression in the brain for gene linked to ALS and FTD

For the first time novel expression sites in the brain have been identified for a gene which is associated with Motor Neuron Disease and Frontotemporal Dementia.

1 Aug 2016

Sheffield researchers identify novel function of C9orf72 protein linked to ALS and FTD

Scientists from the University of Sheffield have discovered a novel function of the C9orf72 protein which is linked to amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) - giving a new insight into the most common genetic cause of the degenerative diseases.

1 Jul 2016

Research sheds new light on biological processes underlying neurodegeneration in AD

Progranulin is a central protein in both neuronal survival and neurodegenerative diseases. It is thus not surprising that altered progranulin levels represent a universal theme shared across several common neurodegenerative diseases.

26 May 2016